Sorafenib inhibits intracellular signaling pathways and induces cell cycle arrest and cell death in thyroid carcinoma cells irrespective of histological origin or BRAF mutational status

Overview of attention for article published in BMC Cancer, March 2015

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
Good Attention Score compared to outputs of the same age (76th percentile)
High Attention Score compared to outputs of the same age and source (84th percentile)

Mentioned by

patent: 3 patents

Citations

dimensions_citation: 45 Dimensions

Readers on

mendeley: 44 Mendeley

Summary Patents Dimensions citations

So far, Altmetric has seen 3 patents that reference this research output.

Cancer therapy by degrading dual MEK signaling

Grant US-11510919-B2

United States of America

ＰＡＣ－１併用療法

Application JP-7033451-B2

Japan

PAC-1 combination therapy

Grant US-11129830-B2

United States of America

This page shows the most recent patents that mention this research output.

Click here to find out how to access more activity.